相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update
Morgan Roupret et al.
EUROPEAN UROLOGY (2021)
B7H4 expression in tumor cells impairs CD8 T cell responses and tumor immunity
Linlin Zhou et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)
Primary and acquired resistance mechanisms to immune checkpoint inhibition in Hodgkin lymphoma
Johanna Veldman et al.
CANCER TREATMENT REVIEWS (2020)
Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer
Jacqueline Vuky et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Antibody targeting of B7-H4 enhances the immune response in urothelial carcinoma
Joseph R. Podojil et al.
ONCOIMMUNOLOGY (2020)
CD8+ T cell states in human cancer: insights from single-cell analysis
Anne M. Van der Leun et al.
NATURE REVIEWS CANCER (2020)
Efficacy of Surgery in the Primary Tumor Site for Metastatic Urothelial Cancer: Analysis of an International, Multicenter, Multidisciplinary Database
Marco Moschini et al.
EUROPEAN UROLOGY ONCOLOGY (2020)
Defining 'T cell exhaustion'
Christian U. Blank et al.
NATURE REVIEWS IMMUNOLOGY (2019)
B7-H4 Modulates Regulatory CD4+ T Cell Induction and Function via Ligation of a Semaphorin 3a/Plexin A4/Neuropilin-1 Complex
Joseph R. Podojil et al.
JOURNAL OF IMMUNOLOGY (2018)
Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: a joint study by the European Association of Urology-Young Academic Urologists and the Upper Tract Urothelial Carcinoma Collaboration
Andrea Necchi et al.
BJU INTERNATIONAL (2018)
Effectiveness of Adjuvant Chemotherapy After Radical Nephroureterectomy for Locally Advanced and/or Positive Regional Lymph Node Upper Tract Urothelial Carcinoma
Thomas Seisen et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
Arjun V. Balar et al.
LANCET (2017)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer et al.
LANCET (2017)
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
Arjun V. Balar et al.
LANCET ONCOLOGY (2017)
New B7 Family Checkpoints in Human Cancers
Ling Ni et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Elements of cancer immunity and the cancer-immune set point
Daniel S. Chen et al.
NATURE (2017)
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
J. Bellmunt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Molecular Pathways: Evaluating the Potential for B7-H4 as an Immunoregulatory Target
Heather L. MacGregor et al.
CLINICAL CANCER RESEARCH (2017)
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells
Jason D. Fontenot et al.
JOURNAL OF IMMUNOLOGY (2017)
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Suzanne L. Topalian et al.
CANCER CELL (2015)
Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses
Ping-Chih Ho et al.
CELL (2015)
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
Chih-Hao Chang et al.
CELL (2015)
CD103+ Tumor Infiltrating Lymphocytes Predict a Favorable Prognosis in Urothelial Cell Carcinoma of the Bladder
Bo Wang et al.
JOURNAL OF UROLOGY (2015)
T cell exclusion, immune privilege, and the tumor microenvironment
Johanna A. Joyce et al.
SCIENCE (2015)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
Patient characteristics and outcomes in metastatic upper tract urothelial carcinoma after radical nephroureterectomy: the experience of Japanese multi-institutions
Nobuyuki Tanaka et al.
BJU INTERNATIONAL (2013)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
Prognostic relevance of preoperative circulating CD8-positive lymphocytes in the urinary bladder recurrence of urothelial carcinoma
Chang-Te Lin et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Lymphadenectomy at the Time of Nephroureterectomy for Upper Tract Urothelial Cancer
Marco Roscigno et al.
EUROPEAN UROLOGY (2011)
Increased Rac1 activity and Pak1 overexpression are associated with lymphovascular invasion and lymph node metastasis of upper urinary tract cancer
Takao Kamai et al.
BMC CANCER (2010)
Regulatory T cells and immune tolerance
Shimon Sakaguchi et al.
CELL (2008)
Inhibitory B7-family molecules in the tumour microenvironment
Weiping Zou et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells
JD Fontenot et al.
NATURE IMMUNOLOGY (2003)
Control of regulatory T cell development by the transcription factor Foxp3
S Hori et al.
SCIENCE (2003)
分享论文
